AAtomic AI uses artificial intelligence to speed up drug discovery, focusing on RNA therapeutics. It provides a platform-as-a-service that leverages deep learning foundation models to discover and design small molecules, medicines, and RNA tools. The platform combines ML with experimental biology to explore RNA structures and predict viable drug candidates, which clients can access via subscriptions and paid collaborations. Compared with competitors, Atomic AI concentrates specifically on RNA targets and RNA-based therapies, offering an integrated AI design toolset plus potential co-development partnerships rather than just one-off software. The company’s goal is to make RNA-targeted drug discovery faster and cheaper for pharmaceutical companies, biotech firms, and academic researchers by providing scalable AI-driven discovery capabilities and collaboration opportunities.
Work here?Claim your company
We're working on gathering enough insights on this company, check back soon!
Industries
Company Size
11-50
Company Stage
Series A
Total Funding
$42M
Headquarters
San Francisco, CA
Founded
2021
See people who can refer or advise you
Total Funding
$42M
Above
Industry Average
Funded Over
2 Rounds
Industry standards
In December 2023, Atomic AI launched a large language model (LLM) based solution, ATOM-1, which leverages chemical mapping data to predict the structure and function of RNA.
PALO ALTO, Calif.--(BUSINESS WIRE)--Playground Global, an early-stage, deep-tech venture firm that invests in founders building category-defining businesses at the forefront of science and technology, today announced that Benjamin Kim PhD, has been promoted to Partner. Ben focuses on identifying founders and companies that are revolutionizing engineered biology, building the future of emerging modality therapeutics development, and unlocking AI and ML workflows to refactor drug development. Ben joined Playground as a Venture Fellow in 2019 while completing his PhD in bioengineering at Stanford University. He became a Venture Associate a year later, and by 2022, he had led investments in two breakthrough biotech companies and was promoted to Venture Principal. In the last year, Ben has supported investments in Insamo (Board Observer and Lead Investor), Infinimmune (Board Director and Lead Seed Investor), Atomic AI (Board Observer and Lead Series A investor) and Amber Bio (Board Observer and Co-Led Seed Investment Round). He has also worked with Outpace Bio and Manifold Bio, where he is a Board Observer
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atomic AI, a biotechnology company fusing cutting-edge machine learning with state-of-the-art structural biology to unlock RNA drug discovery, today announced the appointment of Stuart Peltz, Ph.D. as an independent board member to the Atomic AI Board of Directors, and the additions of Percy Carter, MBA, Ph.D., and Nicholas Meanwell, Ph.D. to their Scientific Advisory Board (SAB). “We are extremely pleased to have these highly regarded, experienced biotech leaders join in our efforts and believe in our mission,” said Raphael Townshend, Ph.D., Founder and CEO of Atomic AI. “Dr. Peltz’s experience will help shape our strategy as we endeavor to streamline the discovery and development of novel therapies
Atomic AI adds Bristol Myers Squibb veteran Dr. Manjunath Ramarao as Chief Scientific Officer.
Atomic AI, a biotechnology company fusing cutting-edge machine learning with state-of-the-art structural biology to unlock RNA drug discovery, launche
Find jobs on Simplify and start your career today
We update Atomic AI's jobs every few hours, so check again soon!Browse all jobs
We're working on gathering enough insights on this company, check back soon!
Industries
Company Size
11-50
Company Stage
Series A
Total Funding
$42M
Headquarters
San Francisco, CA
Founded
2021
Find jobs on Simplify and start your career today
We update Atomic AI's jobs every few hours, so check again soon!Browse all jobs